The pathogenetic bases of cardiorenal syndrome


Cite item

Full Text

Abstract

The term "cardiorenal syndrome" has been introduced to denote the mutual influences of the cardiovascular system and kidneys. According to the definition, the cardiorenal syndrome is a pathophysiological condition of the heart and kidney, in which acute or chronic dysfunction of one of these organs leads to that of the other. The community of pathogenetic components allows one to apply a comprehensive approach to diagnosing, treating, and preventing cardiovascular and renal diseases.

Full Text

Патогенетические основы кардиоренального синдрома. - Аннотация. Для обозначения взаимного влияния сердечно-сосудистой системы и почек введено понятие "кардиоренальный синдром". Согласно определению кардиоренальный синдром - патофизиологическое состояние сердца и почек, при котором острая или хроническая дисфункция одного из этих органов ведет к острой или хронической дисфункции другого. Общность звеньев патогенеза позволяет осуществлять комплексный подход к диагностике, лечению и профилактике сердечно-сосудистых заболеваний и болезней почек.
×

References

  1. Sarnak M.J., Levey A.S., Schoolwerth A.C. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
  2. Ronco C., House A.A., Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957-962.
  3. Моисеев B.C., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармакотер 2002; 3: 16-18.
  4. Mielniczuk L.M. Estimated Glomerular Filtration Rate, Inflammation, and Cardiovascular Events After an Acute Coronary Syndrome. Am Heart J 2008; 155 (4): 725-731.
  5. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и др. Первые результаты национального эпидемиологического исследования - эпидемиологическое обследование больных ХСН в реальной практике (по обращаемости) - ЭПОХА-О-ХСН. Сердеч недостат 2003; 3: 116-120.
  6. Функция почек в особых ситуациях. Приложение 3 к журналу "Кардиоваск тер и проф" 2008; 6. http://www.cardiosite.ru/articles/Article.aspx?articleid=6031&rubricid=13
  7. Мухин Н.А., Моисеев B.C., Кобалава Ж.Д. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер арх 2004; 6: 39-46.
  8. Parikh C.R., Coca S.G., Wang Y. et al. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med 2008; 168 (9): 987-995.
  9. Efendigil M.C., Harley A., Deegan T. et al. Changes in glomerular filtration rate following myocardial infarction. Cardiovasc Res 1975; 9 (6): 741-744.
  10. Intravenous NPA for the treatment of infarcting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21 (24): 2005-2013.
  11. Thrombolysis In Myocardial Infarction 10A - Phase 1 trial. Circulation 1996; 93: 843-846.
  12. Lee S.H., Kim Y.-J., Kim W. et al. Clinical outcomes and therapeutic strategy in patients with acute myocardial infarction according to renal function: data from the Korean Acute Myocardial Infarction Registry. Circ J 2008; 72 (9): 1410-1418.
  13. Abuelo G.J. Normotensive Ischemic Acute Renal Failure. N Engl J Med 2007; 357: 797-805.
  14. Mancia G. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
  15. Mento P.F., Maita M.E., Wilkes B.M. Renal hemodynamics in rats with myocardial infarction: selective antagonism of angiotensin receptor subtypes. Am J Physiol Heart Circ Physiol 1996; 271: 2306-2312.
  16. Zou A.P., Li N., Cowley A.W. Production and actions of superoxide in the renal medulla. Hypertension 2001; 37 (2 Part 2): 547-553.
  17. Brady H.R. Acute renal failure. In: Brenner B.M., ed. Brenner and Rector's the kidney. 7th ed. Philadelphia: Saunders 2004; 1215-1292.
  18. Bongartz L.G., Cramer M.J., Doevendans P.A. et al. The severe cardiorenal syndrome: "Guyton revisited". Eur Heart J 2005; 26 (1): 11-17.
  19. Артериальная гипертензия и почки: вместе навеки? Можно ли разорвать порочный круг? 1332 http://www.rmj.ru/articles_7271.htm
  20. Арабидзе Г.Г., Белоусов Ю.Б., Варакин Ю.Я. и др. Диагностика и лечение артериальной гипертонии. Метод. рекоменд. М: Медицина 1985: 320.
  21. Mogensen C.E. The kidney in diabetes: how to control renal and related cardiovascular complications. Am J Kidney Dis 2001; 37: S2-S6.
  22. Jones C.A., Francis M.E., Eberhardt M.S. et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445-459.
  23. Metclaf P., Baker J., Scott A. et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension and hyperlipidemia. Clin Chem 1992; 38: 1802-1808.
  24. Tsioufis C., Dimitriadis K., Taxiarchou E. et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 2006; 19 (5): 462-466.
  25. Kistorp C., Raymond I., Pedersen F. et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293 (13): 1609-1616.
  26. Bigazzi R., Bianchi S., Baldari D., Campese V.M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-1333.
  27. Jensen J.S., Feldt-Rasmussen B., Borch-Johnsen K. et al. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11 (11): 727-732.
  28. Jensen J.S., Feldt-Rasmussen B.F., Strandgaard S. et al. Microalbuminuria is associated with a fourfold increased risk of ischemic heart disease among hypertensive patients. Ugeskr Laeger 2002; 164 (32): 3773-3777.
  29. Schrader J., Luders S., Kulschewski A. et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study). J Hypertens 2006; 24 (3): 541-548.
  30. Dell'Omo G., Penno G., Giorgi D. et al. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis 2002; 40 (1): 1-8.
  31. Cerasola G., Cottone S., Mule G. et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 14 (7): 915-920.
  32. Wachtell K., Palmieri V., Olsen M.H. et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J 2002; 143 (2): 319-326.
  33. de Zeeuw D., Parving H.H., Henning R.H. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006; 17 (8): 2100-2105.
  34. Redon J., Cea-Calvo L., Lozano J.V. et al. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens 2006; 24 (4): 663-669.
  35. Мухин Н.А. Снижение скорости клубочковой фильтрации - общепопуляционный маркер неблагоприятного прогноза. Тер арх 2007; 6: 5-10.
  36. Majunath G. Level of kidney function as a risk factors for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121-1129.
  37. Culleton B.F., Larson M.G., Wilson P.W. et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-2219.
  38. Bibbins-Domingo K., Chertow G.M., Fried L.F. et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 2006; 166 (13): 1396-1402.
  39. Handly N. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Ann Emerg Med 2004; 44 (2): 191-192.
  40. Рекомендации по лечению "Функциональное состояние почек и прогнозирование сердечно-сосудистого риска". Приложение 3 к журналу "Кардиоваск тер и проф" 2008; № 6.
  41. Хроническая почечная недостаточность. Мед газета 08.07.2005; 52.
  42. Nabeshima Y. Clinical discovery of alpha-Klotho and FGF-23 unveiled new insight into calcium and phosphate homeostasis. Calcium 2008; 18: 923-934.
  43. Shimada T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
  44. Slatopolsky E. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 2001; 37: 54-57.
  45. Floege J., Kim J., Ireland E. et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2010; 26 (6): 1948-1955.
  46. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 Suppl 3): Sl-201.
  47. Hofmann M.A., Lalla E., Lu Y. et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. Clin Invest 2001; 107 (6): 675-683.
  48. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969; 56: 111-128.
  49. Outinen A., Sood S., Pfeifer S. et al. Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells. Blood 1999; 94 (3): 959-967.
  50. Perna A., Satta E., Acanfora F. et al. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 2006; 69: 869-876.
  51. Sarnak M.J., Wang S.R., Beck G.J. et al. Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. Am J Kidney Dis 2002; 40 (5): 932-939.
  52. Chen Y.-F., Li P.-L., Zou A.-P. Effect of Hyperhomocysteinemia on Plasma or Tissue Adenosine Levels and Renal Function. Circulation 2002; 106: 1275.
  53. Gupta A., Robinson K. Hyperhomocysteinaemia and end stage renal disease. J Nephrol 1997; 10 (2): 77-84.
  54. Medina M., Urdiales J., Amores-Sбnchez M. Roles of homocysteine in cell metabolism. Eur J Biochem 2001; 268: 3871-3882.
  55. Virdis A., Ghiadoni L., Salvetti G. et al. Hyperhomocyst(e)inemia: Is this a novel risk factor in hypertension? J Nephrol 2002; 15: 414-421.
  56. Лебедева А.Ю., Михайлова К.В. Гипергомоцистеинемия: современный взгляд на проблему. http://kgt-rgmu.ru/lebedeva.php
  57. Добронравов В.А., Голубев Р.В. Гипергомоцистеинемия - фактор риска сердечно-сосудистых поражений у диализных больных и в общей популяции. Нефрология 2004; 2: 44-49.
  58. Fischer P.A., Dominguez G.N., Cuniberti L.A. et al. Hyper­homocysteinemia Induces Renal Hemodynamic Dysfunction: Is Nitric Oxide Involved? J Am Soc Nephrol 2003; 14: 653-660.
  59. Березов Т.Т., Коровин Б.Ф. Биологическая химия. М: Медицина 1998: 286.
  60. Wang J., Dudman N., Wilcken D. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 1993; 70: 1047-1052.
  61. Loscalzo J. The Oxidant Stress of Hyperhomocyst(e)inemia. J Clin Invest 1996; 98 (1): 5-7.
  62. Welch G., Upchurch G., Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. Ann N Y Acad Sci 1997; 811: 48-58.
  63. Demuth K., Atger V., Benoi M. et al. Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Eur J Biochem 1999; 263: 367-376.
  64. Drunat S., Moatti N., Paul J.L. et al. Homocysteine-induced decrease in endothelin-1 production is initiated at the extracellular level and involves oxidative products. Eur J Biochem 2001; 268: 5287-5294.
  65. Loscher T.F., Oemar B.S., Boulanger C.M., Hahn A.W. Molecular and cellular biology of endothelin and its receptors - part I. J Hypertens 1993; 11: 7-11.
  66. Hofmann M.A., Lalla E., Lu Y. et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. Clin Invest 2001; 107 (6): 675-683.
  67. Chin J.H., Azhar S., Hoffman B.B. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18.
  68. Friedman A.N., Bostom A.G. The Kidney and Homocysteine Metabolism. J Am Soc Nephrol 2001; 12: 2181-2189.
  69. Hultberg B., Andersson A., Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40 (4): 230-235.
  70. Vassalotti J.A., Stevens L.A., Levey A.S. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007; 50 (2): 169-180.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies